Stocks Health care AXSM
NASDAQ · Health careAxsome Therapeutics, Inc. (AXSM)
Axsome Therapeutics, Inc. brought in $865.3M of revenue over the twelve months to September 30, 2026, up 54.2% from a year earlier. It posted a net loss of $157.3M. In fiscal 2025 capital spending exceeded operating cash flow by $93.9M. At September 30, 2026 it held $313.9M in cash against $188.1M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 2, 2026.
Key facts about Axsome Therapeutics, Inc.
- Net worth
- Axsome Therapeutics, Inc. has a market value (market cap) of $7B at the latest share price, and shareholders' equity of $105.4M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $638.5M (+65.5% year on year), with a net loss of $183.2M. Over the 12 months to September 30, 2026: revenue $865.3M, net loss $157.3M.
- Cash flow
- In fiscal 2025 operations used $93.4M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 2, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Axsome Therapeutics, Inc.'s next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Axsome Therapeutics, Inc. does
Axsome Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker AXSM.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $638.5M | -$183.2M | -$3.68 | -$93.9M |
| 2024 | $385.7M | -$287.2M | -$5.99 | -$128.7M |
| 2023 | $270.6M | -$239.2M | -$5.27 | -$145.7M |
| 2022 | $50M | -$187.1M | -$4.60 | -$117.2M |
| 2021 | n/a | -$130.4M | -$3.47 | -$108.5M |
| 2020 | n/a | -$102.9M | -$2.77 | -$78.5M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where AXSM ranks in Health care
Latest SEC filings
What Axsome Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 2, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 52% to $259.7M versus the same quarter last year; diluted EPS -$0.25 versus -$0.94.
- November 2, 2026
- August 10, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 46% to $218.4M versus the same quarter last year; diluted EPS -$0.99 versus -$0.97.
- August 10, 2026
- July 27, 2026Passive stake changed SCHEDULE 13G/A
- July 15, 2026Other event 8-K
- June 9, 2026
- June 9, 2026
- June 3, 2026Other event 8-K
- May 4, 2026Quarterly report 10-Q · period to March 31, 2026Revenue rose 57% to $191.2M versus the same quarter last year; diluted EPS -$1.26 versus -$1.22.
Insider trades
What the people running Axsome Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $2.1M worth of shares in the last 90 days and bought none on the open market. All of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 3, 2026 | Jacobson Mark L.Chief Operating Officer | Exercised options | 10,000 | $129.5K |
| September 3, 2026 | Jacobson Mark L.Chief Operating Officer | Soldpre-planned (10b5-1) | 10,000 | $2.1M |
| August 6, 2026 | Tabuteau HerriotChief Executive Officer, Director, 10% owner | Exercised options | 4,660 | $23.1K |
| August 6, 2026 | Tabuteau HerriotChief Executive Officer, Director, 10% owner | Soldpre-planned (10b5-1) | 4,660 | $997K |
| August 5, 2026 | Tabuteau HerriotChief Executive Officer, Director, 10% owner | Exercised options | 45,004 | $222.8K |
| August 5, 2026 | Tabuteau HerriotChief Executive Officer, Director, 10% owner | Soldpre-planned (10b5-1) | 45,004 | $9.5M |
| July 1, 2026 | Tabuteau HerriotChief Executive Officer, Director, 10% owner | Exercised options | 49,666 | $245.8K |
| July 1, 2026 | Tabuteau HerriotChief Executive Officer, Director, 10% owner | Soldpre-planned (10b5-1) | 49,666 | $11.9M |
Who owns AXSM
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
Largest institutional holders
Insiders
6 insiders reported holding 151,112 shares in total, about $20.2M at the last price.
| Holder | Shares |
|---|---|
| Jeffs RogerDirector | 58,367 |
| Pizzie NickChief Financial Officer | 42,867 |
| Coleman MarkDirector | 30,389 |
| Saad Mark EDirector | 11,431 |
| Tabuteau HerriotChief Executive Officer, Director, 10% owner | 7,229 |
| Mahony SusanDirector | 829 |
Questions about AXSM
What does Axsome Therapeutics, Inc. do?
Axsome Therapeutics, Inc. is a company in the Health care sector, listed on NASDAQ as AXSM. Its shares trade on NASDAQ under the ticker AXSM.
What is Axsome Therapeutics, Inc.'s net worth?
Axsome Therapeutics, Inc. has a market value (market cap) of $7B at the latest share price, and shareholders' equity of $105.4M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Axsome Therapeutics, Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $157.3M on revenue of $865.3M.
How much revenue does Axsome Therapeutics, Inc. make?
Over the twelve months to September 30, 2026 Axsome Therapeutics, Inc. reported revenue of $865.3M. That is 54.2% more than a year earlier.
When did Axsome Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 2, 2026. It covers the period to September 30, 2026.
When is Axsome Therapeutics, Inc.'s next earnings report?
Axsome Therapeutics, Inc.'s next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare AXSM with
Follow AXSM
Get an email when Axsome Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Axsome Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.